Sobi soars as it beats revenue and earnings estimates for 2nd-qtr 2016

15 July 2016

Nordic biotech firm Swedish Orphan Biovitrum (STO: SOBI) has seen its second-quarter 2016 sales reach levels 92% higher than the same period last year, with the latest results sending its share price up by nearly 8% on Friday.

Revenues totalled 1.47 billion Swedish kronor ($173 million), compared to the 764 million kronor in 2nd-qtr 2015, with product sales making up 1.29 billion kroner of this.

The revenue includes a one-off payment of 386 million kroner from US biotech major Biogen (Nasdaq: BIIB) triggered by the first commercial sales of their Alprolix (rFIXFc) extended half-life therapy for hemophilia B.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK